1-(1-Ethoxyethyl)-4-iodo-1H-pyrazole (CAS 575452-22-1): A Key Intermediate in Ruxolitinib Synthesis
In the pharmaceutical industry, the demand for high-quality intermediates continues to rise, especially for complex drug molecules such as Ruxolitinib, a well-known JAK1/JAK2 inhibitor. One of the essential chemical components behind its production is 1-(1-ethoxyethyl)-4-iodo-1H-pyrazole (CAS No. 575452-22-1). This compound plays a vital role in the multi-stage synthetic pathway that leads to the formation of Ruxolitinib. VidgasTech is committed to supplying this intermediate with exceptional precision, purity, and reliability for pharmaceutical research and manufacturing.
Understanding the Importance of Ruxolitinib Intermediates
Ruxolitinib has become a widely used therapeutic solution in the management of myelofibrosis, polycythemia vera, and other conditions involving overactive JAK signaling pathways. The success of its formulation depends significantly on the quality of its core intermediates. Among these, 1-(1-ethoxyethyl)-4-iodo-1H-pyrazole stands out due to its structural relevance in building the pyrazole ring that forms the backbone of the final active pharmaceutical ingredient (API).
What is 1-(1-Ethoxyethyl)-4-iodo-1H-pyrazole (CAS 575452-22-1)?
This compound is a highly specialized pharmaceutical intermediate used in advanced organic synthesis. It exhibits excellent chemical stability and is used extensively in the preparation of complex heterocyclic molecules.
Key Features:
Molecular component supporting Ruxolitinib formation
High purity essential for efficient downstream reactions
Stable and consistent performance in multi-step synthesis
Suitable for both research and industrial-scale production
Its importance lies not only in its role as an intermediate but also in how its purity directly influences the final API yield and quality.
Role in the Synthesis of Ruxolitinib
During Ruxolitinib production, 1-(1-ethoxyethyl)-4-iodo-1H-pyrazole acts as an essential building block for the formation of the core heterocyclic structure. Pharmaceutical manufacturers rely on this intermediate to ensure:
✔ Improved reaction efficiency
✔ Reduced impurities
✔ Better reproducibility across batches
✔ Compliance with global regulatory standards
By integrating high-purity intermediates like this one, manufacturers can achieve smoother synthesis pathways and more reliable API outcomes.
VidgasTech: A Trusted Supplier of Ruxolitinib Intermediates
VidgasTech is a leading provider of pharmaceutical intermediates, offering precision-manufactured compounds tailored for research and industrial use. With a strong focus on quality, consistency, and customer satisfaction, VidgasTech ensures that every batch of CAS 575452-22-1 meets stringent quality parameters.
Why Pharmaceutical Manufacturers Choose VidgasTech:
✔ High purity & analytical validation
✔ Global supply capability
✔ Secure packaging and safe logistics
✔ Technical support for scalable synthesis
✔ Compliance with industry standards
The company’s strong commitment to delivering innovative and dependable chemical solutions has made it a preferred partner for API manufacturers worldwide.
Applications Beyond Ruxolitinib
While its main application lies in forming Ruxolitinib, 1-(1-ethoxyethyl)-4-iodo-1H-pyrazole is also useful in:
Advanced organic chemistry research
Heterocyclic compound development
Custom synthesis projects
Drug discovery and molecular modification
Its versatility makes it valuable for multiple chemical and pharmaceutical developments.
Conclusion
1-(1-ethoxyethyl)-4-iodo-1H-pyrazole (CAS 575452-22-1) is a cornerstone intermediate in the synthesis of Ruxolitinib and other complex heterocyclic molecules. Ensuring the quality and purity of this intermediate is essential for achieving optimal pharmaceutical manufacturing outcomes. VidgasTech continues to lead the way by providing reliable, high-standard intermediates that support the global pharmaceutical industry.
For more information or bulk inquiries, visit the official website: 👉 VidgasTech – Your Trusted Partner for Pharmaceutical Intermediates










